Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by APG Asset Management US Inc.

APG Asset Management US Inc. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 25,728 shares of the biopharmaceutical company's stock after selling 3,237 shares during the period. APG Asset Management US Inc.'s holdings in Gilead Sciences were worth $2,376,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Azimuth Capital Investment Management LLC increased its holdings in shares of Gilead Sciences by 1.1% in the fourth quarter. Azimuth Capital Investment Management LLC now owns 111,615 shares of the biopharmaceutical company's stock worth $10,310,000 after purchasing an additional 1,170 shares during the last quarter. APG Asset Management N.V. grew its holdings in Gilead Sciences by 119.8% during the 4th quarter. APG Asset Management N.V. now owns 1,229,769 shares of the biopharmaceutical company's stock valued at $109,699,000 after buying an additional 670,236 shares in the last quarter. Advisory Services Network LLC increased its stake in Gilead Sciences by 14.4% in the 4th quarter. Advisory Services Network LLC now owns 71,087 shares of the biopharmaceutical company's stock worth $6,566,000 after acquiring an additional 8,970 shares during the last quarter. Abacus FCF Advisors LLC increased its stake in Gilead Sciences by 66.8% in the 4th quarter. Abacus FCF Advisors LLC now owns 125,877 shares of the biopharmaceutical company's stock worth $11,627,000 after acquiring an additional 50,408 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Gilead Sciences by 27.2% during the 4th quarter. Renaissance Technologies LLC now owns 5,329,743 shares of the biopharmaceutical company's stock worth $492,308,000 after acquiring an additional 1,141,219 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Remove Ads

Gilead Sciences Stock Up 2.2 %

NASDAQ:GILD traded up $2.23 during trading hours on Friday, reaching $103.63. The company's stock had a trading volume of 8,683,683 shares, compared to its average volume of 7,501,106. The stock has a 50 day moving average price of $108.34 and a two-hundred day moving average price of $96.89. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market capitalization of $129.04 billion, a P/E ratio of 280.08, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last 90 days. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GILD shares. Piper Sandler raised their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.